u/Secure-ValueInvestor

April 17 (Reuters) - Eli Lilly's newly launched obesity pill was prescribed 1,390 times in ‌the U.S. as of the week ended April 10, according to an analyst who cited IQVIA data.

Novo Nordisk's oral Wegovy had hit 3,071 U.S. prescriptions in the first four days after its launch on January 5.

Novo's pill was prescribed 113,354 times in same week compared to 105,366 prescriptions in the prior week, according to IQVIA. The analytics firm did not immediately respond to Reuters request for comment.

It’s good to see that GLPs focus drugs have these benefits. Should help address the FDA data request.

On the side note, the above seems to put Foundayo in line for diabetes too.